Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer
Conclusion RPLS is a rare, but serious, clinicoradiologic syndrome which has been described as an adverse effect of many anti-angiogenic agents and should also be considered in patients on cediranib who present with neurologic symptoms along with vasogenic edema seen on MRI. If RPLS is suspected, cediranib should be discontinued and blood pressure should be aggressively controlled.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Adenocarcinoma | Avastin | Brain | Brain Cancers | Cancer | Cancer & Oncology | Clinical Trials | Colorectal Cancer | Drugs & Pharmacology | Headache | Investigational New Drugs | Neurology